The clinical research sector is experiencing a profound transformation. Simon Arkell, co-founder and CEO of Ryght, and Dr. Chadi Nabhan, Chief Medical Officer and Head of Strategy, recently explored generative AI as an emerging solution to many of the industry's challenges.
From inefficiencies in trial processes to limited patient access, these barriers prevent patients from receiving potentially life-saving treatments. At Ryght, we are proud to be at the forefront of this change.
Breaking Down Barriers to Participation
One of the most significant obstacles in clinical research is patient access, particularly for those outside major medical hubs. Patients from rural or lower-income areas often miss opportunities to participate in trials that could offer them the newest therapies—immunotherapies, CAR-T, or other targeted treatments. AI presents the potential to break down these barriers and create more equitable access to clinical trials, regardless of where patients live.
Identifying Core Challenges in Clinical Research
The challenges in clinical research are complex but urgent. Dr. Nabhan highlights several operational inefficiencies that delay or limit access to groundbreaking therapies:
- Inefficiencies in Trials: Frequent delays often mean life-saving treatments take over a decade to reach patients.
- Communication Gaps: Fragmented communication among stakeholders—sponsors, Contract Research Organizations (CROs), and research sites—causes delays, further preventing patients from accessing treatments in time.
- Resource Misallocation: Many trials fail to enroll enough patients due to poorly selected sites, wasting resources and prolonging the research timeline.
How AI is Transforming Clinical Trials
Generative AI is already reshaping how clinical trials are conducted, tackling these challenges head-on by enhancing efficiency and improving patient outcomes. Ryght’s AI tools streamline processes that previously took weeks, ensuring more patients access innovative therapies faster.
Improving Communication
AI-powered platforms are key to closing communication gaps within the clinical trial ecosystem. By facilitating real-time data sharing and analysis, AI can help match patients to the right trials and select the best-equipped trial sites to meet enrollment goals. This is crucial in overcoming geographic and logistical barriers that have previously limited patient participation.
Streamlining Documentation
Drafting essential documents, like informed consent forms, can take up to 40 hours. With AI copilots, Ryght has reduced this process to under an hour, allowing faster submissions to institutional review boards (IRBs) and helping trials proceed without unnecessary delays. Matching patients to the right trials is a race against time, and AI helps ensure that no valuable time is wasted.
Educating and Empowering Stakeholders
AI's success depends not only on technology but on the willingness of stakeholders to embrace it. Ryght’s tools empower healthcare providers with insights into the latest AI advancements, helping them stay informed and close the knowledge gap between traditional methods and new, AI-driven solutions. Collaboration between stakeholders is key to unlocking the full potential of AI in clinical trials.
Ryght: Leading the Way in AI-Powered Clinical Research
At Ryght, we are committed to driving change in clinical trials through the power of AI. Our platform integrates commercial and open-source language models to develop tools tailored to the specific needs of the clinical research community. As Simon explains, AI is the future of clinical research, and now is the time to fully leverage its potential. By helping stakeholders create customized AI applications, Ryght sets a new standard for operational efficiency and trial success.
Embrace the Future of Clinical Trials with AI
The future of clinical trials is shaped by AI, providing enhanced efficiency, improved patient outcomes, and greater access. Our experts highlight that we possess the technology and expertise needed to address these challenges. It is now essential for all stakeholders to embrace this change, ensuring clinical trials are more accessible and optimized for greater success.
Explore the Ryght platform or try Ryght Preview today to unlock AI's full potential and redefine clinical trials with innovative, future-ready solutions.
